Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Conditions
Brief summary
Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses. Finding new ways to diagnose and treat cardiomyopathies could improve the health and well-being of patients with these conditions. This study will collect data from individuals with cardiomyopathy or related heart muscle disease, or with a possible genetic predisposition to cardiomyopathy, and follow them over time to observe the progress of their heart and health. This study will collect DNA, blood samples, and detailed clinical & lifestyle information at the start of the study, and data collected during routine healthcare visits over time. * learn what causes cardiomyopathy, and therefore how to treat it * understand why cardiomyopathy progresses differently in different people, to improve the ability to recognise who will benefit from different treatments at different times The investigators will collaborate with other centres internationally to collect a large of group of participants with similar cardiomyopathies, providing power to identify new pathways that cause disease and ways of predicting which participants are at risk of having more severe disease.
Interventions
OTHERBlood Sample Collection
Blood for DNA and biomarker analysis
Sponsors
Imperial College London
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Adults with the capacity to consent Children with parental/guardian consent Male and Female Meeting the following criteria: 1. Patients with a confirmed diagnosis of cardiomyopathy or related condition 2. Patients with a family member with cardiomyopathy, or a related condition 3. Patients with a genetic variant that may predispose to cardiomyopathy, or a related condition
Exclusion criteria
Patients without the capacity to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of genetic variants | 5 years | Rare and common genetic variants in people with cardiomyopathy |
| The incidence of major adverse cardiovascular events over 5 years | 5 years | The incidence of major adverse cardiovascular events over 5 years, defined as:- 1. Cardiovascular death 2. Major arrhythmic events (ventricular fibrillation, unstable sustained ventricular tachycardia, appropriate implantable cardioverter-defibrillator delivered shock, and aborted sudden cardiac death) 3. Major heart failure events (heart transplantation, left ventricular assist device implantation, unplanned heart failure hospitalisation) |
Countries
United Kingdom
Contacts
Primary ContactStudy Coordinator
Outcome results
None listed